Locally advanced invasive cervical cancer is treated by chemoradiation therapy that involves administration of chemotherapeutic agent concurrently with radical radiation therapy[@ref1]. Cisplatin is the commonly used chemotherapeutic agent in the case of cervical cancer which sensitizes the tumour cells to radiation therapy by inducing DNA damage[@ref1][@ref2]. Although chemoradiation therapy has significantly improved the outcome of patients with invasive cervical cancer, response to treatment is variable and difficult to predict within a given tumour stage. It is well known that chemotherapy as well as radiation therapy induces cell death and is also associated with inhibition of cell proliferation and decreased cell survival[@ref3]. Ionizing radiation (IR) induces DNA damage by the disruption of many signal transduction cascades responsible for maintaining cellular homeostasis and the interactions between the cells and extracellular matrix resulting in cell death which usually takes place by apoptosis[@ref4][@ref5]. However, the exact molecular mechanisms and the determinants of radiation response intrinsic to the tumour are not well understood and hence there is a need for identifying markers (genetic and epigenetic), which can prognosticate and predict the response of a given patient[@ref6]. In an *in vitro* study on HeLa and SiHa cells, we have previously shown that cisplatin modulates methylation pattern and gene expression of various genes, thereby affecting response to chemotherapy[@ref7]. Hence, we designed this pilot study to evaluate *in vivo* changes in the methylation and gene expression profiles in response to chemoradiation therapy in patients with locally advanced invasive cervical cancer. For this study genes involved in DNA repair (*BRCA1*, *MLH1*, *MGMT* and *DAPK1*), apoptosis (*BAX* and *BCL2L1*), tumour suppressors (*RASSF1A*) and others (*hTERT*, *MYOD1* and *ESR1*) were selected. All these genes have been shown to be hypermethylated with a frequency of methylation ranging from 20 to 70 per cent in invasive cervical cancer excluding genes which showed a very high or a very low frequency of promoter methylation[@ref8][@ref9][@ref10][@ref11][@ref12][@ref13]. In our previous study on a large group of cervical cancer patients unmethylated *MYOD1*, unmethylated *ESR1* and methylated *hTERT* promoters as well as lower *ESR1* transcript levels were shown to predict chemoradiation resistance[@ref14]. The patients included in this study were from a subset of the cohort wherein paired biopsies prior to and following 10 Gy chemoradiation treatment were evaluated.

Material & Methods {#sec1-2}
==================

This study was carried out after approval by the Institute\'s Ethics Committee (vide letter no. 7985/PG/1Trg/09/10242) in the Molecular Pathology Laboratory, department of Cytology and Gynecological Pathology, in collaboration with the departments of Gynaecology and Obstetrics and Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Patients were recruited voluntarily from 2009 to 2011 after obtaining an informed written consent, and the experiments were carried out in 2014-2015.

A total of 20 patients (age range: 34-65 yr, mean age: 49.8±8.55) were included in the study. All patients were histologically proven cases of invasive squamous cell carcinoma, non-keratinizing type. A small portion of the routine pre-treatment cervical biopsy performed for histopathological diagnosis was snap frozen and stored at −80°C. The paired post-chemoradiation therapy sample was obtained after 10 Gy radiation. This dose of 10 Gy was chosen in light of previous studies that have shown peak apoptosis to occur with 9 Gy radiation and tissue necrosis at higher radiation doses when molecular evaluation is not possible[@ref11][@ref15]. The chemoradiation protocol consisted of 40 mg/m[@ref2] cisplatin along with 10 Gy radiation in five fractions given in the first week; following this, a biopsy was obtained from the tumour. After confirmation of the histopathological diagnosis and evaluation of touch imprint smear to confirm that it contained at least 70 per cent tumour tissue, the samples were subjected to molecular analysis.

*Treatment protocol and follow up*: All patients were in FIGO (International Federation of Gynaecology and Obstetrics) Stage IIB/III (7 patients were in Stage IIB and 13 were in Stage III) and were treated identically with chemoradiation therapy. The patients were administered with 46 Gy in 23 fractions external beam radiation concurrently with 40 mg/m^2^ cisplatin weekly dose with three-dimensional conformal radiotherapy using a four-field box technique followed by intracavitary brachytherapy (two fractions of 9 Gy high-dose rate delivered one week apart). All patients were followed up clinically with relevant clinical and radiological investigations performed during the follow up which included haemogram, detailed clinical examination, biochemical evaluation including renal and liver function tests, ultrasonography and computed tomography (CT) scan of pelvis, abdomen and chest. All patients were followed up every two months for the first year, every three months until five years and six months after five years. Patients without pelvic control within the radiation portals were considered as locoregional failures \[local evidence of disease (LED)\] which included patients with residual cervical disease and/or presence of pelvic lymph nodes while on treatment or recurrence, which occurred 1-18 months after completion of the chemoradiation protocol. The remaining patients who were disease free \[no evidence of disease (NED)\] on follow up ranging from 36 to 60 months after completion of the chemoradiation protocol were considered chemoradiation sensitive.

The effect of chemoradiation therapy on gene promoter methylation and transcript levels of *ESR1*, *BRCA1*, *RASSF1A*, *MYOD1*, *MLH1*, *hTERT*, *MGMT*, *DAPK1*, *BAX* and *BCL2L1* genes was evaluated by comparing pre-treatment sample with a second post-treatment sample obtained after 10 Gy chemoradiation treatment. The gene promoter methylation status was evaluated as percentage methylation using methylation PCR arrays. The transcript copy numbers were derived by absolute quantification using quantitative reverse transcription PCR (RT-qPCR).

*DNA/RNA extraction*: DNA/RNA was extracted from the tissue samples using TRIzol reagent (Invitrogen, USA) following manufacturers' instructions and were stored at −80°C till further analysis.

*Gene promoter methylation analysis by methylation PCR arrays*: The percentage methylation of the gene promoter was analyzed by the EpiTect Methyl II PCR Array (SABiosciences Qiagen, Hilden, Germany) following manufacturer\'s instructions. DNA (1 μg) was mixed with 26 μl of 5× Restriction digestion buffer and RNase/DNase-free water was added to make a final volume of 120 μl. The reaction was further divided into four separate reaction tubes, each tube containing 28 μl of the above mix and the tubes were labelled as Mo, Ms, Md and Msd. To Mo, no enzyme was added, 1 μl methylation-sensitive enzyme A was added to Ms, 1 μl methylation-dependent enzyme B was added to Md, 1 μl methylation-sensitive enzyme A and 1 μl methylation-dependent enzyme B were added to Msd and the total volume was adjusted to 30 μl by the addition of RNase/DNase-free water. The components were mixed gently with pipette and incubated at 37°C for 8-10 h, and the reaction was stopped by heating at 65°C for 20 min. This digested DNA was used as template to detect change in methylation status of the sample after treatment by qPCR. The c~p~ (crossing point) of each digested sample was put into EpiTech Methyl II PCR Array software (SABiosciences Qiagen, Hilden, Germany), and the relative fractions of methylated and unmethylated DNA were subsequently determined by comparing the amount in each digest with that of a mock (no enzymes added) digest using a ΔCT method following manufacturer\'s protocol. The amount of hypermethylated target DNA copies was derived as follows: 2^\[−Ct(Ms−Mo)−CR\]/(1−CR)^, where CR represents the amount of target DNA copies resistant to enzyme digestion and is defined as 2^−Ct(Msd−Mo)^. The amount of unmethylated DNA was determined as 2^\[−Ct(Md−Mo)−CR\]/(1−CR)^. All experiments were carried out in duplicates to ensure reproducibility.

*Quantification of gene transcript levels by quantitative reverse transcription PCR (RT-qPCR)*: Purified and intact total RNA was converted to cDNA using the RevertAid™ First strand cDNA Synthesis Kit (Fermentas Life Sciences, USA) according to manufacturer\'s instructions. Gene transcript levels of all the genes under study were analyzed by RT-qPCR using absolute quantification method carried out with the Light Cycler 480 (Roche Applied Science, Mannheim, Germany) as described previously in detail[@ref14][@ref15][@ref16].

*Statistical analysis*: The data were statistically analysed using GraphPad Prism version 5.0 for windows (GraphPad Software Inc., La Jolla, CA, USA). Normality of quantitative data was checked by measures of Kolmogorov-Smirnov tests of normality[@ref17]. Differences in the DNA methylation profile and gene transcript expression profile of pre- and post-treatment samples were analyzed using paired Student\'s t test and Wilcoxon signed rank test (whichever applicable). Correlation of gene promoter methylation to gene transcript levels status was analyzed by Spearman\'s rank Correlation.

Results {#sec1-3}
=======

*Evaluation of change in gene promoter methylation pattern in response to chemoradiation therapy*: The differences in the methylation profile of paired samples following treatment varied from sample to sample. The differences in the mean levels of methylation in the pre-treatment versus post-treatment biopsies are shown in [Fig. 1](#F1){ref-type="fig"}. Overall, the mean percentage methylation of *hTERT*, *RASSF1A* and *BAX* genes was increased and mean percentage methylation of *DAPK1*, *MGMT* and *BRCA1* genes was decreased in post-treatment samples, whereas the other genes studied did not show any change. Only *BAX* gene promoter methylation showed a significant increase in response to chemoradiation treatment (*P*\< 0.01).

![Bar graph showing mean change in gene promoter methylation levels in paired pre- and post-chemoradiation therapy samples of invasive cervical cancer. Values are shown as mean±SD (n=20). \*\**P*\<0.01 compared to pre value.](IJMR-147-151-g001){#F1}

*Evaluation of change in gene transcript levels in response to chemoradiation therapy*: Absolute quantification was performed to derive copy numbers of transcript levels. The median levels in the pre-treatment versus post-treatment sample were compared and results are shown in [Fig. 2](#F2){ref-type="fig"}. The gene transcript levels of *BRCA1* (*P\<0.01*), *DAPK1* and *ESR1* (*P*\< 0.05) genes were significantly increased, whereas *MYOD1* and *MLH1* genes were significantly decreased (*P*\< 0.05).

![Dot plot showing comparison of transcript levels (copy number) in paired pre- and post-chemoradiation therapy samples of invasive cervical cancer. Median values are shown as horizontal bars (n=20). *P* \*\<0.05, \*\*\<0.01 compared to respective pre values.](IJMR-147-151-g002){#F2}

*Correlation of gene promoter methylation to gene transcript level status*: There was a significant correlation of *BAX* and *BCL2L1* gene promoter methylation with corresponding gene transcript expression (Spearman\'s rho=0.461, *P*=0.003 and Spearman\'s rho=0.327, *P*=0.039, respectively). However, none of the other genes showed a significant correlation with gene expression.

*Patient response to chemoradiation therapy*: All patients were followed up clinically and all except one responded to the chemoradiation treatment instituted to them and were free of disease at three years follow up. The single case who had LED in this subset of 20 patients showed increase in methylation of *DAPK1*, *MGMT* and *BRCA1* and increased transcript levels of *RASSF1A* and *MLH1* in addition to increased transcript levels of *BRCA1*, *DAPK1*, *ESR1* and *hTERT* following chemoradiation as compared to the remaining 19 cases.

Discussion {#sec1-4}
==========

The overall survival in invasive cervical cancer is around 50 per cent and the prognosis depends on tumour stage, pelvic lymph node metastasis, tumour volume and vascular invasion in recurrent disease[@ref18][@ref19]. Patients with invasive cervical cancer are treated primarily by chemoradiation which involves administration of cisplatin along with radiation therapy in the form of intracavitary brachytherapy and external radiation. This is more effective than radiation therapy alone in the treatment of invasive cervical cancer and has improved the overall five-year survival rate from 30 to 50 per cent in Stage II and III patients to about 50 to 70 per cent[@ref1][@ref20]. It is well recognized that radiation treatment induces cell death by both cellular necrosis and apoptosis; however, cellular biological aspects of response to radiation/chemoradiation therapy are not well understood[@ref21]. Gene expression profiling studies using microarrays have shown large-scale alterations in genes involved in DNA repair, cell cycle, cell proliferation and apoptosis, angiogenesis and cell-matrix interactions[@ref5]. A few studies have evaluated molecular alterations following chemoradiation therapy. In one report, biopsy samples from pre- and mid-treatment (chemoradiation) cervical tumours were evaluated using single-color oligo-microarrays, and upregulation of *CDKN1A*, *BAX*, *TNFSF8* and *RRM2B* gene transcripts was observed[@ref21]. In a study by Bae *et al*[@ref22], the effect of IR on colon cancer cells (*in vitro*) was evaluated after exposure with 2 and 5 Gy irradiation and it was observed that IR induced genome-wide DNA hypomethylation. *MGMT* promoter methylation has been shown to be associated with improved response to radiation/chemoradiation therapy in glioblastomas[@ref23][@ref24][@ref25]. In the present pilot study, we evaluated the changes in the gene promoter methylation and gene expression in paired pre- and post-chemoradiation biopsies. The post-treatment biopsy was taken after 10 Gy of fractionated radiotherapy over one week as in previous studies[@ref11][@ref15][@ref21]. Tissue viability was maintained at this dose of radiation permitting the study of molecular alterations. We have reported previously in an *in vitro* study that cisplatin affects promoter methylation and the expression pattern of the genes under study and subsequently affects patient\'s response to therapy[@ref7]. The present study was an extension of our observation and was carried on patient samples (*in vivo*) to evaluate changes in the gene promoter methylation and gene expression profile of the patients with invasive cervical cancer treated by chemoradiation therapy. Similar changes were observed in the methylation and gene expression profile post-therapy as observed earlier[@ref7]; however, it was observed that the changes induced were variable from sample to sample. An overall increase in the methylation of *hTERT*, *RASSF1A* and *BAX* genes was seen, whereas methylation of *DAPK1*, *MGMT* and *BRCA1* genes was decreased in post-treatment biopsy samples. The fold change was also variable and ranged from 0 to 100 per cent. Only *BAX* gene methylation showed a significant increase post-chemoradiation. In a previous study on the immunohistochemical expression of Bax, Bcl-2 and Bcl-x1, an increased Bax protein expression was observed in post-RT samples[@ref11]. It is likely that the expression of the pro-apoptotic Bax is not repressed by methylation. The pro- and anti-apoptotic members of the Bcl-2 family are known to have post-transcriptional regulation, especially by microRNAs and other mechanisms such as phosphorylation by kinases which are hyperactive in cancers[@ref26].

In contrast to gene promoter methylation, striking changes were observed in the transcript levels of many genes. There was a significant increase in the tissue transcript levels of *BRCA1*, *DAPK* and *ESR1* and a small but significant decrease in gene transcript levels of *MYOD1* and *MLH1*. The upregulation of *BRCA1* transcript may be viewed as a cellular response to DNA damage as it is involved in the repair of damaged DNA. *DAPK1* is a pro-apoptotic gene that induces apoptosis by gamma interferon and potentially inhibits metastasis[@ref27]; therefore, decreased methylation corresponding to increased expression in post-RT samples suggested that the tumour cells were subjected to apoptosis. The implications of the increase in *ESR1* transcript and decrease in *MYOD1* transcript levels are not clear. *ESR1* encodes the oestrogen receptor protein which has no direct role in the cell death mechanism and *MYOD1* gene encodes for a protein that regulates myogenic differentiation. Both are related to the levels of cellular differentiation with *MYOD1*, a marker of cellular dedifferentiation and *ESR1* is associated with better differentiated cells of the cervical epithelium[@ref13][@ref28].

Decreased transcript levels of *MLH1* post-chemotherapy were observed in our study. Previous reports have shown loss of hMLH1 protein expression to be associated with chemotherapy resistance in ovarian and other tumours[@ref29]; however, existing data on cervical cancer with regard to *hMHL1* expression status and methylation are limited. One group has found loss of hMLH1 protein expression in invasive lesions[@ref30], whereas others have found the opposite[@ref31]. Further, presence of microsatellite instability appears to correlate with a worse prognosis[@ref32] but not with response to cisplatin in a neoadjuvant setting in cervical cancer[@ref33].

It is important to note that all except one patient had no evidence of disease at 36 months' follow up. Therefore, the clinical implications of our findings need to be ascertained by inclusion of cases which are chemoradiation resistant and compare it to the chemoradiation-sensitive patients. To conclude, chemoradiation therapy appears to induce epigenetic changes in DNA methylation pattern and alterations in gene transcript levels in tissues of invasive cervical cancer which may have implications to understand the biology of tumoral radiation response.
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